Cerebellar DBS in SCA1 and SCA3 Study
Key facts
- Who runs it
- Gordon H. Baltuch
- Where
- Cleveland and New York, United StatesSee the 2 sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 12 people, planned
- Starts
- Dec 2026
- Expected to end
- Jun 2030
- Type of study
- Interventional
- Treatments tested
- UG3NS140720 Deep Brain Stimulation System
- Record updated
- 29 October 2026
Who can take part
- Age
- 18 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Subject is aged >= 18 years and =< 60 years
- Subject has moderate ataxia severity, as demonstrated by a Scale for Ataxia Rating and Assessment (SARA) score >= 11
- Subject has genetic confirmation of pathological repeat expansions in ATXN1 (for SCA1, repeat size >= 40) and ATXN3 (for SCA3, repeat size >= 56)
- Subject has been on a stable and optimized standard of care (SoC) regimen for at least 3 months prior to Screening (including physical therapy) and continues to exhibit signs of cerebellar ataxia
- Subject has a minimum 6th grade reading level, as determined by the Rapid Estimate of Adult Literacy in Medicine (REALM) scale
- Subject is able and willing to give informed consent and attend all study visits
- Subject is available for all follow-up visits during the length of the study
Who cannot take part
- Subject is enrolled in another device, biologic or pharmaceutical study within 30 days of consent in the current study (i.e., patients cannot be enrolled if participation in another study was not completed at least 30 days prior to consent)
- Subject has a diagnosis of epilepsy
- Subject has a major active psychiatric illness that may interfere with the study, such as psychiatric disorders or severe personality disorders
- Subject has contraindications to DN DBS, including significant small vessel ischemic disease, vertebrobasilar vascular disease, and/or any other structural abnormalities of the cerebellum, cerebellar peduncles, and brain stem that would preclude safe placement of the DBS leads
- Subject has a condition that, in the opinion of the investigator, would significantly increase the risk for interference with study compliance, safety, or outcome
- Subject is unable to stop anticoagulation or platelet anti-aggregation therapy for study procedures
- Subject is unable to provide informed consent
- Subject has presence of overt tremor, dystonia, and/or parkinsonism, which are atypical features and could be suggestive of prominent extra-cerebellar circuit involvement that may not respond well to cerebellar DBS
- Subject is wheelchair dependent and may be too progressed to complete gait assessments
- Subject has a Montreal Cognitive Assessment (MoCA) score =< 24
- Subject has an untreated or inadequately treated major depressive episode
- Subject is pregnant, lactating, or planning to become pregnant during the study
- For women of childbearing potential, subject is unable or unwilling to use accepted contraception methods
- Subject is unable to communicate with investigators or staff
- Subject has contraindications to magnetic resonance (MR) imaging, e.g., weight incompatible with scanner, implanted metallic devices or electrical devices (pacemaker, defibrillator, spinal cord stimulator), or intolerance to MRI contrast agents
- Subject has evidence of behavior(s) consistent with alcohol or substance abuse/dependence within the preceding 6 months, as outlined by the DSM-V criteria
- Subject is at risk for suicide, defined by a total score >= 3 on the Columbia Suicide Severity Rating Scale (C-SSRS)
- Patients who are not able to read, speak and/or understand English
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Where in United States
- Cleveland ClinicCleveland, United StatesContact: Jeffrey NegreyNot yet recruiting
- Columbia University Irving Medical Center (CUIMC) / NewYork Presbyterian Hospital (NYP)New York, United StatesContact: Natasha DesaiNot yet recruiting
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety and feasibility of deep brain stimulation (DBS) in the deep cerebellar nuclei (DCN) in patients with Spinocerebellar Ataxia (SCA) types 1 and 3.
Read full original descriptionShow less
Primary Objective: The incidence and nature of treatment-related adverse events across the entire study, including serious treatment-related adverse events such as intracerebral hemorrhage, infection, and serious or unanticipated adverse device effects (SADEs and UADEs).
Secondary/Exploratory Objectives:
* Evaluation of the effect of Dentate Nucleus (DN) - Deep Brain Stimulation (DBS). Ataxia severity will be quantified using the Scale of Assessment and Rating of Ataxia (SARA), Patient-Reported Outcome Measure of Ataxia (PROM-Ataxia), and kinematics. * To characterize electrophysiological activity across the cerebellothalamocorticomuscular (CTCM) network at rest and during motor behaviors. * To examine how DN-DBS modulates oscillatory activity and coupling across the CTCM circuit in relation to improvements in controlling ataxia.
The group in the trial
- DBS InterventionTreatment being tested
Participants will undergo surgical implantation of the DBS leads, followed by a second surgery to implant a pulse generator (IPG) which generates electricity.
Treatment: UG3NS140720 Deep Brain Stimulation System
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Deep Brain Stimulation of the Deep Cerebellar Nuclei in Subjects With Spinocerebellar Ataxia: A Safety and Feasibility Study
- Criteria questions
- Built from NCT07752095, who can take part
- Record updated
- 29 October 2026